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A B S T R A C T
Background: Despite extensive use of inhaled corticosteroid/long-acting β2-agonist combinations in asthma,
limited data evaluating dose–response for this combination class are available. The beneﬁts of dose es-
calation and nature of patient subgroups likely to beneﬁt are thus ill-deﬁned.
Method: In this randomised, double-blind, 8-week study the effects of two dose levels (100/10 and 500/
20 μg b.i.d.) of a ﬁxed combination of ﬂuticasone/formoterol (ﬂutiform®) were compared in 309 patients.
Treatment effects upon spirometric and symptom-based endpoints were examined in the overall pop-
ulation and in two subgroups deﬁned a priori by % predicted FEV1 at baseline (≥40–≤60% [“severe” airways
obstruction] and >60–≤80% [“moderate” airways obstruction]).
Results: No dose–response was evident for spirometric outcomes (FEV1, FEV1 AUC0–12, PEFR) either overall
or in either subgroup. At variance with the spirometric data, statistically signiﬁcant dose-dependent dif-
ferences were seen for nocturnal outcomes and consistent numerical differences were found acrossmultiple
symptom-based outcomes (symptom scores, sleep scores, rescue medication use, asthma control days,
AQLQ scores, exacerbations); greater effects were noted with the higher dose of ﬂuticasone/formoterol.
Between-group differences for the overall population were driven by treatment effect differences in the
“severe” subgroup.
Conclusion: In this exploratory comparison a high dose of ﬂuticasone/formoterol in asthmatic patients
appears to provide additional improvement in symptom-based rather than spirometric outcomes. Ad-
ditional beneﬁts from high versus low dose treatment are most likely in patients with severe airway
obstruction, although the doses at which ceiling effects are attained may vary between individuals.
Trial registration: ClinicalTrials.gov identiﬁer: NCT00734318; EudraCT number: 2007-001633-34.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Background
Clinical development of ﬁxed combination drugs for asthma, such
as ﬂuticasone propionate/salmeterol or budesonide/formoterol, has
historically involved extrapolation of the dose levels approved (or
shown to be effective) for the monoproducts to derive an appro-
priate ﬁxed combination dose. In pivotal phase 3 studies, a single
dose level of the ﬁxed combination has then been compared to
equivalent doses of one or more of the constituent monoproducts
[1,2]. As a result of such practice, reﬂecting the fact that regulato-
ry authorities have not previously required head-to-head dose level
comparisons to support a proposed dose range for the combina-
tion, there are few data directly comparing different dose levels of
an inhaled corticosteroid/long-acting β2-agonist (ICS/LABA) despite
the use of this class in asthma management for approximately 15–
20 years. Indeed no published data are available in asthmatic subjects
regarding the comparative clinical effects of ﬂuticasone/salmeterol,
beclometasone/formoterol or ﬂuticasone furoate/vilanterol at dif-
ferent dose levels; whilst only one study has directly compared
different dose levels of budesonide/formoterol [3] alongside three
further budesonide/formoterol studies in which two dose levels were
evaluated albeit not directly compared [4–7]. A single further study
evaluating two dose levels of mometasone/formoterol is available
again without a direct pairwise analysis [8]. As a result of this sparse
evidence base the feasibility of demonstrating dose–response is
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uncertain and there is little guidance for prescribers as to when dose
escalation of an ICS/LABAmay bewarranted. In recent years however,
European regulatory authorities have become increasingly inter-
ested in dose–response data suggesting that the provision of such
data will increase which in turn may allow more informed treat-
ment decisions to be made.
In this paper we present the results of a post hoc analysis in which
two dose levels of ﬂutiform®, an ICS/LABA comprising ﬂuticasone
propionate and formoterol fumarate in combination (ﬂuticasone/
formoterol) in a pressurised metered-dose inhaler were compared
in an exploratory manner. The study has been previously reported
[9] but here we focus solely on the comparison of ﬂuticasone/
formoterol dose levels, in an attempt to shed light on dose–
response for ICS/LABAs and provide insights into the utility of current
regulatory guidelines.
2. Methods
The details of the study protocol and main ﬁndings have been
published elsewhere [9]. Brieﬂy, this was a double-blind, double-
dummy, parallel-group study. Adults (≥18 years) with a history of
asthma characterized by ICS treatment with ≥500 μg ﬂuticasone
or equivalent, a pre-bronchodilator FEV1 of ≥40% to ≤80% pre-
dicted, and FEV1 reversibility of ≥15% post-salbutamol were eligible
for inclusion. Patients discontinued their usual asthma medica-
tions and entered a 2-week open-label run-in period in which
they were given ﬂuticasone 250 μg twice daily (b.i.d.) (Flixotide®,
GlaxoSmithKline, UK). Patients uncontrolled at the end of this
run-in (i.e., who required rescue medication for at least 3 days,
and had at least 1 night with sleep disturbance or at least 3 days
with asthma symptoms during the last 7 days of the run-in
period) were randomised inter alia to 8 weeks treatment with one
of two doses of ﬂuticasone/formoterol (500/20 μg or 100/10 μg
b.i.d.; ﬂutiform® hydroﬂuoroalkane [HFA] pMDI) via a spacer
(AeroChamber Plus®, Trudell Medical International, UK). This com-
parison therefore entailed a ﬁve-fold difference in ICS and a
two-fold difference in LABA dose. Randomisation was stratiﬁed by
% predicted FEV1 at baseline (≥40–≤60% versus >60–≤80%) which
provided a straightforward basis for a dichotomised subgroup
analysis by baseline FEV1 severity.
2.1. Patients
The co-primary endpoints were the mean change in morning
pre-dose FEV1 from baseline to the end of treatment; and the
mean change in FEV1 from morning pre-dose at baseline to 2 h
post-morning dose at the end of treatment. Secondary eﬃcacy
endpoints of interest can be classiﬁed as “spirometric”, i.e. mean
12-h FEV1 area under the curve (AUC0–12) at day 0 and day 56 (in a
subset of 48% of patients) and daily morning and evening peak
expiratory ﬂow rate (PEFR); and “symptom-related”, i.e. asthma
symptoms scores, symptom free days, sleep disturbance scores,
Table 1
Demographic and Baseline Spirometric Characteristics for high and low dose ﬂuticasone/formoterol pMDI dichotomised by percentage predicted FEV1 at baseline (ITT Population).
Endpoint Fluticasone/formoterol 500/20 μg b.i.d. (high
dose)
Fluticasone/formoterol 100/10 μg b.i.d. (low
dose)
N 154 155
Mean age [years (SD)] 50.5 (14.4) 48.0 (13.9)
- FEV1 ≤60% predicted subgroup 51.1 (14.11) 48.6 (14.10)
- FEV1 >60% predicted subgroup 49.8 (14.76) 47.4 (13.80)
Male/female [n (%)] 56 (36.4)/98 (63.6) 60 (38.7)/95 (61.3)
- FEV1 ≤60% predicted subgroup 38 (48.1)/41 (51.9) 31 (40.3)/46 (59.7)
- FEV1 >60% predicted subgroup 18 (24.0)/57 (76.0) 29 (37.2)/49 (62.8)
Mean duration of asthma [years(SD)] 12.7 (11.82) 13.5 (12.49)
- FEV1 ≤60% predicted subgroup 12.8 (12.46) 12.0 (10.86)
- FEV1 >60% predicted subgroup 12.6 (11.18) 14.9 (13.84)
Median ICS requirement pre-study [μg FP-equivalent/day
(range)]
500 (250–1500) 500 (80–1500)
- FEV1 ≤60% predicted subgroup 500 (250–1500) 500 (80–1000)
- FEV1 >60% predicted subgroup 500 (400–1000) 500 (250–1500)
LABA co-administration pre-study [n (%)] 118 (76.6) 112 (72.3)
- FEV1 ≤60% predicted subgroup 63 (79.7) 53 (68.8)
- FEV1 >60% predicted subgroup 55 (73.3) 59 (75.6)
Mean FEV1 reversibility [% (SD)] 31.6 (17.29) 30.5 (15.08)
- FEV1 ≤60% predicted subgroup 32.9 (19.76) 31.8 (15.67)
- FEV1 >60% predicted subgroup 30.2 (14.24) 29.2 (14.47)
Mean FEV1 predicted at Day 0 [%(SD)] 60.0 (10.94) 60.3 (10.33)
- FEV1 ≤60% predicted subgroup 51.00 (5.37) 51.84 (5.34)
- FEV1 >60% predicted subgroup 69.54 (6.21) 68.66 (6.56)
Mean pre-dose FEV1 at Day 0 [L (SD)] 1.73 (0.52) 1.81 (0.58)
- FEV1 ≤60% predicted subgroup 1.51 (0.42) 1.54 (0.45)
- FEV1 >60% predicted subgroup 1.97 (0.51) 2.09 (0.56)
Mean morning pre-dose PEFR at Day 0 [L/min (SD)] 310.7 (124.45) 312.7 (124.52)
- FEV1 ≤60% subgroup 310.1 (138.56) 308.5 (138.78)
- FEV1 >60% subgroup 311.3 (108.56) 316.8 (109.38)
Mean evening pre-dose PEFR at Day 0 [L/min (SD)] 315.5 (123.10) 321.7 (125.55)
- FEV1 ≤60% predicted subgroup 313.7 (139.98) 317.2 (140.12)
- FEV1 >60% predicted subgroup 317.4 (103.29) 326.1 (110.03)
Day 0: baseline; FP: ﬂuticasone propionate; SD: standard deviation.
FEV1 ≤60% predicted subgroup: N = 79 in ﬂuticasone/formoterol high dose group and N = 77 in ﬂuticasone/formoterol low dose group; FEV1 >60% predicted subgroup: N = 75
in ﬂuticasone/formoterol high dose group and N = 78 in ﬂuticasone/formoterol low dose group.
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awakening free nights, asthma control days, rescue medication
use, asthma exacerbations and asthma quality of life question-
naire (AQLQ) scores.
2.2. Statistical analysis
Analysis of all endpoints was based on the ITT population. The
ITT population included all randomised patients who received at
least one dose of study treatment and had at least one post-dose
primary eﬃcacy variable (FEV1) measurement.
Change from baseline in pre-dose FEV1, 2-h post-dose FEV1,
morning and evening PEFR, asthma symptom scores, percentage of
symptom-free days, sleep disturbance scores, percentage of
awakening-free nights, percentage of asthma control days, percent-
age of rescue medication-free days and AQLQ scores at the end of
treatment were analysed using Analysis of Covariance (ANCOVA)
with treatment as a factor, asthma severity and baseline value as
covariates and centre as a random effect. 12-h serial FEV1 AUC at
Day 0 and end of treatment were analysed using ANCOVA with
asthma severity and pre-dose FEV1 as covariates. Missing values were
imputed using the last observation carried forward.
The proportion of patients experiencing any asthma exacerba-
tions and severe asthma exacerbations were analysed using Fisher’s
exact test.
The following post-hoc analyses were also performed: analysis
of annualized exacerbation rates using a negative binomial model
with treatment as a factor and length of exposure as an offset vari-
able; analysis of the proportion of patients achieving an increase
(improvement) in AQLQ score of ≥0.5 units using a logistic regres-
sion model with treatment as a factor, and overall AQLQ score at
Day 0 as a covariate; and subgroup analysis of all endpoints ac-
cording to FEV1% predicted category at baseline (≤60%, >60%), the
dichotomy which provided the basis for stratiﬁed randomisation.
3. Results and discussion
3.1. Patients
At the end of the 2-week run-in period (on ﬂuticasone 250 μg
b.i.d.), 309 patients were randomised to the two doses of ﬂuticasone/
formoterol with stratiﬁcation according to % predicted FEV1 (≤60%
or >60%).
The two ﬂuticasone/formoterol treatment groups (155 pa-
tients allocated to 100/10 μg b.i.d.; 154 to 500/20 μg b.i.d.) were
well balanced in terms of demographics and baseline asthma char-
acteristics. Similarly characteristics of the FEV1 ≤60% subgroup (77
patients allocated to 100/10 μg b.i.d.; 79 to 500/20 μg b.i.d) were
similar in each treatment group as were those of the FEV1 >60% sub-
group (78 patients allocated to 100/10 μg b.i.d.; 75 to 500/20 μg
b.i.d) (Tables 1 and 2).
3.2. Spirometric eﬃcacy parameters
The co-primary endpoints of the change in pre- and 2-h post-
dose FEV1 at study end from pre-dose FEV1 at baseline demonstrated
numerically greater effects with the high versus low dose of
ﬂuticasone/formoterol (Fig. 1). However, the between-group dif-
ferences were neither statistically signiﬁcant nor clinically relevant
(pre-dose FEV1 0.04 L, (95% CI −0.07, 0.16; p = 0.437); 2-h post-
dose FEV1 0.01 L (95% CI −0.10, 0.12; p = 0.840)). Regarding other
spirometric endpoints (the change in morning and evening diary
PEFR at study end from baseline and FEV1 AUC0−12 at day 0 and day
56) there was again no difference between high and low ﬂuticasone/
formoterol dose groups (Fig. 1). The 95% conﬁdence intervals for
these differences weremore or less symmetrically distributed around
the line of unity essentially illustrating the similarity of spiromet-
ric effects with both dose levels (Fig. 1).
Table 2
Baseline Symptom-Related Characteristics for high and low dose ﬂuticasone/formoterol pMDI dichotomised by percentage predicted FEV1 at baseline (ITT Population).
Endpoint Fluticasone/formoterol 500/20 μg b.i.d. (high dose) Fluticasone/formoterol 100/10 μg b.i.d. (low dose)
N 154 155
Mean % symptom-free days at Day 0 (SD) 16.14 (22.91) 21.38 (26.32)
- FEV1 ≤60% predicted subgroup 17.18 (23.37) 21.52 (26.18)
- FEV1 >60% predicted subgroup 15.05 (22.51) 21.25 (26.63)
Mean % asthma control days at Day 0 (SD) 9.00 (16.73) 9.95 (16.95)
- FEV1 ≤60% predicted subgroup 7.78 (14.97) 7.33 (15.21)
- FEV1 >60% predicted subgroup 10.29 (18.43) 12.25 (18.06)
Mean % awakening-free nights at Day 0 (SD) 46.10 (37.37) 50.23 (38.19)
- FEV1 ≤60% predicted subgroup 45.21 (37.20) 46.75 (38.96)
- FEV1 >60% predicted subgroup 47.04 (37.78) 53.66 (37.35)
Mean % rescue medication-free days at Day 0 (SD) 15.68 (21.03) 15.67 (20.77)
- FEV1 ≤60% predicted subgroup 15.37 (21.19) 14.10 (20.66)
- FEV1 >60% predicted subgroup 16.00 (21.00) 17.22 (20.89)
Mean asthma symptom scores at Day 0 (SD) 1.17 (0.61) 1.10 (0.63)
- FEV1 ≤60% predicted subgroup 1.15 (0.63) 1.11 (0.59)
- FEV1 >60% predicted subgroup 1.19 (0.58) 1.06 (0.62)
Mean sleep disturbance scores at Day 0 (SD) 0.65 (0.57) 0.58 (0.54)
- FEV1 ≤60% predicted subgroup 0.63 (0.52) 0.62 (0.57)
- FEV1 >60% predicted subgroup 0.67 (0.62) 0.54 (0.53)
Mean AQLQ scores at Day 0 (SD) 4.42 (0.89) 4.56 (0.93)
- FEV1 ≤60% predicted subgroup 4.47 (0.93) 4.55 (0.92)
- FEV1 >60% predicted subgroup 4.34 (0.83) 4.55 (0.94)
Day 0: baseline; SD: standard deviation; AQLQ: Asthma Quality of Life Questionnaire.
FEV1 ≤60% predicted subgroup: N = 79 in ﬂuticasone/formoterol high dose group and N = 77 in ﬂuticasone/formoterol low dose group; FEV1 >60% predicted subgroup: N = 75
in ﬂuticasone/formoterol high dose group and N = 78 in ﬂuticasone/formoterol low dose group.
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Subgroup analysis of the above spirometric endpoints with the
population dichotomised according to % predicted FEV1 at base-
line also failed to demonstrate statistically or clinically signiﬁcant
differences between the low and high ﬂuticasone/formoterol dose,
or any consistent trends (Fig. 2 and Table S1).
3.3. Symptom-related eﬃcacy parameters
Results for symptom-related endpoints in the study are
summarised in Fig. 3.
Although the study was not powered to evaluate treatment dif-
ferences for symptom-based endpoints, statistically signiﬁcant
differences (at the 5% level) were noted for the change in sleep dis-
turbance scores (−0.12 units; p = 0.005) and the change in the
percentage of awakening free nights (9.87%; p = 0.002), (Fig. 3) in
favour of high dose ﬂuticasone/formoterol. A numerical difference
in favour of the high dose was observed for asthma symptom scores,
symptom-free days, AQLQ scores and the annualized rate of exac-
erbations. Consistent treatment effect differences across almost all
symptom-based endpoints, and the distribution of the associated
95% conﬁdence intervals illustrated in Fig. 3, suggested an overall
beneﬁt in favour of high dose ﬂuticasone/formoterol.
Subgroup analyses of the symptom-related endpoints accord-
ing to percentage predicted FEV1 at baseline (≤60% and >60%) were
undertaken, as for the spirometric endpoints (see Fig. 4 and
Tables S2–S4).
These subgroup analyses showed that overall treatment effect
differences between the ﬂuticasone/formoterol high and low doses
for the symptom-related endpoints were consistently more evident
in the “severe” FEV1 subgroup. In the latter subgroup the differ-
ences were statistically signiﬁcant for change in sleep disturbance
scores, change in percent of awakening-free nights and change in
AQLQ scores and were close to being statistically signiﬁcant for 3
other endpoints (change in asthma symptom scores [p = 0.085], an-
nualized rate of asthma exacerbations [p = 0.064], and the proportion
of subjects attaining an increase in AQLQ ≥ 0.5 units [p = 0.080]).
By contrast in the “moderate” subgroup, other than for nocturnal
symptoms, there was no difference between high and low doses of
ﬂuticasone/formoterol for the symptom-based endpoints. Overall,
for all 11 symptom-based endpoints treatment effect differences
between high and low dose ﬂuticasone/formoterol were greater in
the “severe” than in the “moderate” subgroup. Notably, baseline
symptom scores were similar in these two subgroups.
3.4. Safety
There was no evidence of an adverse qualitative or quantita-
tive dose-related effect on safety. Adverse events were reported in
19.5% and 18.7% of the ﬂuticasone/formoterol high and low dose
groups, respectively. The most common adverse events were na-
sopharyngitis (1.9% and 1.3%, respectively), pharyngitis (1.3% and 1.3%,
respectively) and asthma (1.9% and 1.9%, respectively). Two pa-
tients in each dose group (1.3%) reported severe asthma
exacerbations as adverse events. There were no reports of biochem-
ical or clinically overt adrenal axis suppression. No subjects in either
group experienced serious adverse events. Six patients in the high
dose group withdrew due to a lack of eﬃcacy (3.9%) compared to
18 (11.6%) in the low dose group (difference −7.7% [95% CI: −13.6,
−1.8]; p = 0.018). Clinical laboratory evaluations were unremark-
able: effects upon glucose and potassium revealed no consistent
differences between treatment groups.
4. Conclusions
To our knowledge, this is only the second clinical study to ex-
plicitly compare the effects of two dose levels of a ﬁxed dose
combination ICS/LABA upon spirometric and patient-centred out-
comes in asthmatic patients, and the ﬁrst to assess dose–response
in subgroups of patients with moderate and severe airways ob-
struction. Aubier et al. reported a six month, open-label study
comparing budesonide/formoterol 400/12 μg b.i.d. versus 200/
6 μg b.i.d. administered as maintenance and reliever therapy [3].
Comparative data for different dose levels of budesonide and
formoterol in combination [4–7] and for a ﬁxed combination of
mometasone/formoterol [8] are also available from four further
studies although none of these include inferential comparisons
between treatment groups in which different dose levels are used.
No comparable data are available for other ICS/LABA combina-
tions such as ﬂuticasone propionate/salmeterol or beclometasone/
Fig. 1. Spirometric treatment differences (95% CIs) between high and low dose
ﬂuticasone/formoterol pMDI (Overall ITT population). LS = Least Squares; Day 0 = Base-
line; CI = Conﬁdence Interval; AUC = Area Under the Curve.
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formoterol. In the present study the top and bottom daily dose levels
of the ﬂuticasone/formoterol dose range were evaluated, since mul-
tiple previous studies have shown minimal pairwise differences in
effect between contiguous dose levels of ICS and β2-agonist
monotherapies in asthma [10–16].
A potential criticism of this study is its short duration. However,
with corticosteroid-based therapy improvement of lung function
and symptom control in asthma is typically rapid, occurring within
one to two weeks [17]. Treatment effects other than airways
hyperresponsiveness are generally (near-) maximal within 1–3
months in most patients, and several long-term studies have dem-
onstrated that key conventional endpoints, such as lung function
effects and symptom scores, are sustained but do not usually improve
substantially beyond improvements seen at 1–2 months with ICS
monotherapy or ICS/LABA combinations [18–20]. Furthermore treat-
ment differences for lung function, symptoms and rescue medication
use between different ICS/LABAs or between ICS/LABAs and ICSs are
typically static over 2–12 months or increase modestly but in the
same direction as that seen at early time points [19,20]. In a similar
manner treatment differences in event based outcomes (such as ex-
acerbations) are either static or increase in magnitude in the same
direction between 2 and 12 months [20,21]. In view of these ob-
servations the treatment differences observed over 8 weeks in our
study have reasonable predictive value over the longer-term.
Randomisation in our study was stratiﬁed by percent pre-
dicted FEV1, which provided a simple means for a dichotomised
subgroup analysis of “moderate” and “severe” patients. The lack of
any consistent evidence of dose–response for standard
Fig. 2. Spirometric treatment differences (95% CIs) between high and low dose ﬂuticasone/formoterol pMDI dichotomised by percentage predicted FEV1 at baseline (ITT
population). LS = Least Squares; Day 0 = Baseline; CI = Conﬁdence Interval; AUC = Area Under the Curve.
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spirometric endpoints in the overall population in our study echoes
the shallow and inconsistent spirometric dose–response reported
in the literature for all classes of inhaled drugs used to treat ob-
structive lung disease [5,10,12,22,23]. Nonetheless a similar lack of
any dose–response in the “severe” subgroup was perhaps surpris-
ing particularly given the extent of airways obstruction (mean 51.4%
predicted FEV1) which might have been expected to manifest as a
right shift of the dose–response curve.
The contrast with the pattern observed acrossmultiple symptom-
based endpoints in our study was noteworthy. Signiﬁcant differences
at the 5% level between high and low doses of ﬂuticasone/formoterol
or trends in favour of the high dose were noted for a number of
symptom-related endpoints although the study was not formally
powered to evaluate these outcomes. Overall dose-dependent di-
rectional consistency was evident across 10 of 11 symptom-based
endpoints.
Support for the observed pattern of treatment effects in our study
is available from FACET [5,6]. Interpretation of the FACET data is com-
plicated by the fact that the authors did not present a pairwise
comparison of high versus low dose levels of budesonide/formoterol.
Nonetheless, the symptom-related dose–response trends in our study
largely echo those apparent in FACET; in FACET high dose
budesonide/formoterol afforded consistent incremental beneﬁts in
terms of lower day- and night-time symptom scores, improved health
status, and lesser rescue medication use, whilst the exacerbation
rate was approximately halved with the high (800/24 μg) versus low
dose (200/24 μg) dose of budesonide/formoterol. As in our study,
in FACET there was no apparent dose–response for FEV1. Other pub-
lished studies evaluating two dose levels of budesonide and
formoterol or mometasone and formoterol in combination show less
evidence of dose–response than FACET [3,4,7,8]; however, all these
studies evaluated dose-levels separated by only a two-fold multi-
ple of one or both components which reinforces our rationale for
comparing ﬂuticasone/formoterol over the widest available dose
range in the present study. Dose–response patterns in earlier ICS/
LABA studies and the wider literature suggest that the ﬁve-fold
increase in ﬂuticasone dose is primarily responsible for treatment
effect differences in our study compared to the two-fold increase
in formoterol dose. Interestingly however, Aubier and colleagues ob-
served that post-bronchodilator PEFR and post-bronchodilator FEV1
at baseline were somewhat stronger predictors of patients likely to
beneﬁt with a higher (400/12 μg) versus lower (200/6 μg) dose of
budesonide/formoterol than the corresponding pre-bronchodilator
indices [3]. This may suggest that a component of dose–response
in Aubier’s study (in which an 18% reduction in time to exacerba-
tions and exacerbation rate were reported), and in our own study,
is due to the two-fold multiple of formoterol in the high versus low
dose groups.
Treatment differences between high and low dose ﬂuticasone/
formoterol in our study were modest for a number of symptom-
based endpoints in the overall population and for some of these,
such as rescue-free days and asthma control days, were clearly not
of a clinically relevant magnitude. For other endpoints however dose
comparisons hinted at more meaningful differences. These differ-
ences were accentuated in the “severe” subgroup: for every
symptom-based endpoint the difference between dose levels was
greater in the “severe” than in the “moderate” subgroup. Thus in
the “severe” subgroup, treatment effect differences appeared to be
relatively large for some of the endpoints assessed: with high versus
low dose ﬂuticasone/formoterol the exacerbation rate was 45% lower,
the odds of an AQLQ “response” (≥0.5 unit increase) was almost twice
as high, there was a 43% relative increase in awakening-free nights
and 21% relative increase in symptom-free days. Even in the “severe”
subgroup however, there was little evidence of a meaningful re-
duction in rescue medication use, whilst the increase in asthma
control days still appeared to be of borderline utility (a 14% rela-
tive increase).
From a practical perspective our data suggest that patients with
the most compromised lung function are those in whom dose es-
calation is most likely to beworthwhile in the event of partial control
with low dose ﬂuticasone/formoterol treatment, and that symp-
tomatic gainsmay largely relate to exacerbation risk reduction, health
status improvement and less sleep disturbance. Conﬁrmation of these
hypotheses is required in future studies.
Statistical signiﬁcance at the 5% level was only demonstrated for
a few symptom-based endpoints. This is because the comparison
between high and low dose ﬂuticasone/formoterol was
Fig. 3. Symptom-related treatment differences (95% CIs) between high and low dose
ﬂuticasone/formoterol pMDI (Overall ITT population). AQLQ = Asthma Quality of Life
Questionnaire; CI = Conﬁdence Interval.
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exploratory and not formally powered to evaluate treatment effect
differences for symptom-based endpoints. In this context it is im-
portant to understand the meaning of a result such as the
exacerbation rate ratio of 0.55 (p = 0.064) seen with high versus low
dose treatment in the “severe” subgroup. Whilst failing to satisfy
the conventional, and arbitrary, 5% false positive threshold (i.e., as-
sociated with p = 0.05) a result such as this (which implies a 6.4%
probability that the observed difference happened by chance) is still
meaningful to generate a hypothesis for evaluation in future studies.
With a larger sample size several borderline statistical results would
likely have become signiﬁcant at the 5% level.
Notably, a dose–response is not evident for standard lung func-
tion indices but appears to exist for symptom-related endpoints.
Differing patterns of dose–response for these different endpoints
may be reﬂective of different mechanisms. While FEV1 and PEFR
mainly reﬂect large airways responses, clinical outcomes such as
nocturnal asthma [24], exacerbations [25,26] and asthma control
[27,28] have been previously related to dysfunction of the periph-
eral airway zone. It is thus tempting to speculate that while the
central lung is readily saturable with low doses of inhaled drug, high
doses may provide additional beneﬁt in severe patients by increas-
ing drug deposition in the peripheral compartment.
Fig. 4. Symptom-related treatment differences (95% CIs) between high and low dose ﬂuticasone/formoterol pMDI dichotomised by percentage predicted FEV1 at baseline
(ITT population). AQLQ = Asthma Quality of Life Questionnaire; CI = Conﬁdence Interval.
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The ﬁndings in this study are relevant to regulatory authori-
ties. Conventional lung function indices are the most standard,
accepted primary eﬃcacy variables [29,30] in regulatory studies in-
tended to facilitate product approval. However, given the increased
regulatory focus on assay sensitivity and a desire for a clear dem-
onstration of dose–response, it is important that regulators are aware
that this may not be feasible, at least with ICS/LABAs, using con-
ventional spirometric endpoints in studies which are externally valid
(i.e., do not speciﬁcally recruit enriched populations of selected dose–
responsive patients).
In conclusion, our study suggests that treatment beneﬁts with
higher versus lower doses of ﬂuticasone/formoterol may be iden-
tiﬁable for symptom-based but not spirometric parameters. Patients
with more severe airways obstruction appear to be those most likely
to gain additional beneﬁt from higher treatment doses, with clin-
ically relevant beneﬁts primarily appearing to relate to exacerbation
risk reduction, health status and sleep disturbance. These explor-
atory observations require conﬁrmation in studies speciﬁcally
designed and powered to assess dose–response.
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